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Abstract
 
The intraportal injection of human pancreatic islets has
been indicated as a possible alternative to the pancreas
transplant in insulin-dependent diabetic patients. Aim of
the present work was to study the effect of intraportal injec-
tion of purified human islets on: (
 
a
 
) the basal hepatic glu-
cose production; (
 
b
 
) the whole body glucose homeostasis
and insulin action; and (
 
c
 
) the regulation of insulin secretion
in insulin-dependent diabetes mellitus patients bearing a
kidney transplant. 15 recipients of purified islets from ca-
daver donors (intraportal injection) were studied by means
of the infusion of labeled glucose to quantify the hepatic
glucose production. Islet transplanted patients were subdi-
vided in two groups based on graft function and underwent:
(
 
a
 
) a 120-min euglycemic insulin infusion (1 mU/kg/min) to
assess insulin action; (
 
b
 
) a 120-min glucose infusion (
 
1
 
75
mg/dl) to study the pattern of insulin secretion. Seven pa-
tients with chronic uveitis on the same immunosuppressive
therapy as grafted patients, twelve healthy volunteers, and
seven insulin-dependent diabetic patients with combined
pancreas and kidney transplantation were also studied as
control groups. Islet transplanted patients have: (
 
a
 
) a higher
basal hepatic glucose production (HGP: 5.1
 
6
 
1.4 mg/kg/
min; 
 
P
 
 
 
,
 
 0.05 with respect to all other groups) if without
graft function, and a normal HGP (2.4
 
6
 
0.2 mg/kg/min)
with a functioning graft; (
 
b
 
) a defective tissue glucose dis-
posal (3.9
 
6
 
0.5 mg/kg/min in patients without islet function
and 5.3
 
6
 
0.4 mg/kg/min in patients with islet function) with
respect to normals (
 
P
 
 
 
,
 
 0.01 for both comparisons); (
 
c
 
) a
blunted first phase insulin peak and a similar second phase
secretion with respect to controls. In conclusion, in spite of
the persistence of an abnormal pattern of insulin secretion,
successful intraportal islet graft normalizes the basal HGP
and improves total tissue glucose disposal in insulin-depen-
dent diabetes mellitus. (
 
J. Clin. Invest.
 
 1996. 97:2611–2618.)
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Introduction
 
Increased hepatic glucose production and insulin resistance
are common features of poorly controlled insulin-dependent
diabetes mellitus (IDDM)
 
1
 
 both before and after the develop-
ment of chronic renal failure (1–3). Insulin therapy (4) and
segmental and whole pancreatic transplantation (5–10) were
shown to normalize the glycosylated hemoglobin, the hepatic
glucose production, and to ameliorate insulin action in IDDM
patients, leading to a near-normalization of glucose homeosta-
sis. Frequent hypoglycemic episodes are a common finding in
patients on intensive insulin therapy (4), while peri- and post-
surgical morbidity (and also some hypoglycemic episodes) are
associated with intact pancreas transplant (11, 12). To date, is-
let transplantation in humans has rarely achieved normoglyce-
mia and suspension of insulin therapy (5, 13). Therefore, as-
sessment of the effect of a long-term normalization of glucose
concentration on insulin action and glucose homeostasis was
not feasible in IDDM patients with an islet graft due to the
limited number of patients with functioning grafts available. In
the present study, we combined the clinical experience of Mi-
lan, Italy and Giessen, Germany to measure hepatic glucose
production, insulin action, and insulin secretory pattern in 15
patients with intraportal islet transplantation. This study shows
that functioning islet grafts normalize basal hepatic glucose
output and ameliorate insulin action notwithstanding the need
to administer immunosuppressive drugs.
 
Methods
 
Subjects. 
 
14 insulin-dependent diabetic patients were studied after
islet and kidney transplantation. 11 subjects received the islet trans-
plant after the kidney graft (IAK), while three of them received the
islets simultaneously with the kidney (SIK). One additional patient
received the liver and the islet transplant simultaneously (SIL). We
studied a total of 15 patients which allowed us to reach a statistical
power of at least 90% (to detect differences at a 0.05 level) for the pa-
rameters under study. No single population (either in Milan or in
Giessen) would have been sufficient to achieve a comparable statisti-
cal power. Pancreases were obtained from cadaver donors. Islet were
separated using an automated procedure, after the injection of Hank’s
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1. 
 
Abbreviations used in this paper:
 
 CON, healthy subjects; CU,
patients with chronic uveitis; F, islet-transplanted patients with func-
tioning graft; HGP, hepatic glucose production; IDDM, insulin-
dependent diabetes mellitus; MCR, metabolic clearance rate; NF, is-
let-transplanted patients with nonfunctioning graft; PAN, diabetic
patients with intact pancreas transplant.
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solution containing Collagenase (Boehringher Mannheim Biochemi-
cals, Indianapolis, IN). Islets were purified and separated from the
exocrine pancreas by centrifugation on density gradients (Ficoll, DL-
400; Sigma Chemical Co., St. Louis, MO). In all cases purified islets
were injected into the liver via the portal vein. The patient’s clinical
and laboratory data are represented in Table I. All biochemical and
clinical parameters presented in the table were stable during the 4 wk
preceding this investigational protocol.
We subdivided the 15 patients with islet graft into two subgroups
on the basis of the success of the transplant: F, 8 patients with, and
NF, 7 patients without function. Four major criteria were used: (
 
a
 
) ca-
pacity of the graft to secrete insulin (using the c-peptide concentra-
tion as a parameter); (
 
b
 
) fasting plasma glucose; (
 
c
 
) percentage of gly-
cosylated hemoglobin after insulin suspension (or on low-dose insulin
treatment) for at least 4 wk; and (
 
d
 
) daily insulin dose. Obviously, for
each of the four parameters chosen as indexes of function, it was nec-
essary to determine a cut-off point between functioning and nonfunc-
tioning grafts. This was a critical issue for the present work. Using the
most conservative criteria (1. c-peptide concentration 
 
.
 
 1.8 ng/ml; 2.
F.P.G. 
 
,
 
 140 mg/dl; 3. glycosylated hemoglobin 
 
,
 
 6.5%; 4. patient off
insulin [or injecting 5–8 U/d] for at least 4 wk, only 3 of 15 patients
could be considered to have graft function at the time of study (pa-
tients F4, F7, and F8, Table I). By allowing one or two of the four pa-
rameters to escape the set limit (with the exception of c-peptide, con-
sidered fixed), the number of patients considered to have function at
the time of the study (and at least for the preceding 4 wk) increased
to eight (patients F1–F8; Table I). We have used the less stringent cri-
terion to analyze the data for the following reasons: (
 
a
 
) using both cri-
teria, the fasting c-peptide concentration was 
 
z
 
 2 ng/ml; (
 
b
 
) a small
amount of daily insulin was often injected discretionally by the pa-
tients still on insulin, to optimize the glycemic control; and (
 
c
 
) finally,
re-analyzing the data using the most strict criterion (e.g., comparing
three patients with function with the patients without function) the
major conclusions of the present work do not change. Interestingly,
two patients (F3 and NF2) had partial function (fasting c-peptide of
1.8 and 1.4 ng/ml, respectively). In contrast, the remaining six patients
were nearly without function.
We also studied a group of seven nondiabetic patients with chronic
uveitis (CU) on the same immunosuppressive regimen as islet-trans-
planted patients to define the effect of chronic immunosuppression per
se on the parameters under evaluation. Seven patients (PAN) with in-
tact pancreas and kidney transplantation (standard transplant therapy
for IDDM associated with uremia) were studied using the hypergly-
cemic clamp technique to compare the regulation of insulin secretion
of intrahepatic islets with that of an intact pancreas transplant in IDDM.
Since the population of diabetic patients was approximately half Ital-
ian and half German, we also studied 12 healthy volunteers (CON, 6
studied in Giessen, Germany and 6 studied in Milan, Italy), to control
for possible ethnic, dietary, and environmental differences (Table II).
 
Table I. Clinical and Biochemical Parameters of IDDM Patients after Pancreatic Islet Transplantation at the Time of the Present 
Study Subdivided in Functioning (F) and Nonfunctioning (NF)
 
Patients Sex SIK/IAK Age BMI HbA1
Insulin
pre Tx Insulin Prednis. CyA Aza
Days of
transpl. F.P.G.
Fasting
C-peptide
Serum
creatinine
Diabetes
duration Islet #
 
yr % U/d U/d mg/d mg/d mg/d mg/dl ng/ml mg/dl yr
 
F1 F IAK 38 22 6.6 46 8 7.5 225 0 361 153 2.1 4.9 33 350900
F2 M IAK 41 21 7 62 6 7.5 225 0 180 139 4.8 3.2 39 770000
F3 M IAK 31 20 5.8 67 18 15 300 0 134 110 1.8 1.2 11 1244400
F4 M SIL 48 22 6 40 0 10 800 0 67 113 2.1 1.4 1 820000
F5 F IAK 40 22 5 32 5 5 280 56 399 98 2.05 0.9 36 482150
F6 M SIK 48 20 7.2 60 0 10 270 54 144 101 2.96 1 30 910375
F7 F IAK 53 23 5.6 49 0 7 265 53 230 102 1.99 1 37 612500
F8 M IAK 50 23 6.5 40 0 10 275 55 25 120 4.6 1.3 35 592500
Mean 44 21.6 6.2 49.5 4.6 9 330 27 192 117 2.8 1.8 28 722853
SE 2.6 0.42 0.26 4.3 2.2 1.1 68 10 47 7 0.4 0.5 5 98587
NF1 M IAK 30 23 6.5 40 60 30 400 0 30 176 0.02 1.8 32 521000
NF2 M IAK 43 21 5.2 30 55 10 300 50 71 103 1.4 1.5 35 1060000
NF3 M IAK 43 23 6.5 68 36 25 250 0 62 362 0.23 1.2 43 583500
NF4 M IAK 49 27 7.6 42 68 25 200 0 58 420 0.14 2 44 597900
NF5 M IAK 39 22 6.5 48 45 4 300 60 423 147 0.02 0.7 27 1294125
NF6 M SIK 41 24 7.1 40 40 10 270 54 714 162 0.42 1.5 36 248500
NF7 M SIK 38 23 9.1 60 90 10 260 52 132 222 0.04 0.8 22 180000
Mean 40 23.2 6.9 53 56 16.2 283 31 213 227 0.32 1.4 34 640717
SE 2.2 0.71 0.45 7.3 7 3.8 23 11 99 45 0.18 0.18 3 153396
 
P
 
NS 0.052 NS NS
 
,
 
 0.0001 0.072 NS NS NS 0.021
 
,
 
 0.0001 NS NS NS
Aza, azathioprine; SIK, simultaneous islet and kidney transplant; IAK, islet after kidney transplant; SIL, simultaneous islet and liver transplant; FPG,
fasting plasma glucose.
 
Table II. Clinical and Biochemical Parameters of Patients
with Chronic Uveitis (CU), Normal Subjects (CON), and
Pancreas-transplanted Patients (PAN)
 
Chronic uveitis
(CU)
Normal subjects
(CON)
Pancreas
transplanted
patients (PAN)
 
Age (yr) 40
 
6
 
2 38
 
6
 
5 36
 
6
 
3
Sex (males/females) 5/2 9/3 5/2
BMI (kg/m
 
2
 
) 22.9
 
6
 
2.1 23.0
 
6
 
2.0 22.1
 
6
 
1.9
HbA1 (%) 5.8
 
6
 
0.4 5.6
 
6
 
0.3 6.0
 
6
 
0.4
Prednisone (mg/d) 12
 
6
 
3
 
2
 
9
 
6
 
3
CyA (mg/kg/d) 5
 
6
 
1
 
2
 
6
 
6
 
1
Azathioprine (mg/kg/d)
 
2 2
 
1.1
 
6
 
0.3
Serum creatinine (mg/ml) 1.1
 
6
 
0.2 0.9
 
6
 
0.2 1.2
 
6
 
0.3
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Experimental protocol. 
 
(Figs. 1 and 2). A similar experimental pro-
tocol was performed in the metabolic units of San Raphael Hospital
in Milan, Italy and the Third Department of Medicine and Policlinic
at the Justus-Liebig-Universität in Giessen, Germany. The experi-
mental protocol was approved by the Ethical Committees of both the
San Raphael Hospital and the Justus-Liebig-Universität. All the ex-
periments were performed by Dr. Livio Luzi (both in Italy and in
Germany) to guarantee uniformity of experimental techniques and
comparability of data analysis. Therefore, the in vivo experimental
techniques, the laboratory techniques, and the analysis of data were
identical for all subjects.
All study subjects were admitted to the ward the night before the
study at 5:00 p.m. They were maintained on a diet of at least 250 g of
carbohydrates and 70–80 g of proteins per d for the 2 wk preceding
the study. In the four islet transplanted patients receiving some units
of insulin, the intermediate-acting insulin was withdrawn at least 36 h
before the study, and no regular insulin was injected after 1:00 p.m.
the day before the study. At 7:00 a.m. on the day of the study, two
plastic catheters were placed into forearm veins for the infusion of
study solutions and arterialized blood drawing as previously de-
scribed (10). Due to specific radioprotection guidelines of the Federal
Republic of Germany all patients studied in Giessen (F1, F2, F3, NF1,
NF2, NF3, NF4) received a [6,6-d
 
2
 
]-glucose to quantify whole-body
glucose metabolism. [3-
 
3
 
H]-glucose infusion was performed as de-
scribed (10) in all patients studied in Milan (F4, F5, F6, F7, F8, NF5,
NF6, NF7). Study 1: (Fig. 1). After a tracer equilibration period ade-
quate to achieve tracer’s steady state in plasma (a minimum of 90–120
min), all study subjects belonging to groups F, NF, CU, and CON un-
derwent a euglycemic hyperinsulinemic clamp (1 mU/kg/min), lasting
an additional 120 min. In groups F, CU, and CON, the plasma glucose
concentration was maintained at euglycemia (
 
z
 
 100 mg/dl), while in
group NF the plasma glucose was clamped at 
 
z
 
 180 mg/dl. Study 2:
(Fig. 2). Four patients with functioning islet transplantation (F), all
the patients with chronic uveitis (CU), the normal controls (CON),
and the diabetic patients with intact pancreas transplantation (PAN)
received a 
 
1
 
 75 mg/dl hyperglycemic clamp to stimulate insulin secre-
tion (Fig. 2). The desired glucose level during the hyperglycemic
clamp was chosen to match the post-prandial glucose concentration
(
 
z
 
 180 mg/dl).
Plasma glucose, plasma tritiated glucose specific activities, and
plasma deuterated glucose enrichments were assessed every 10–30
min in the last hour of the basal equilibration period and during the
120 min of the euglycemic study. During the euglycemic clamp, the
plasma free insulin, plasma c-peptide, and plasma glucagon were
Figure 1. This figure depicts the 
experimental protocol of Study 1 
(1 mU/kg/min insulin infusion, 
maintaining euglycemia). The 
steady state post-absorptive con-
centrations as well as the time-
dependent variation of free insu-
lin, c-peptide and glucagon during 
the 120-min insulin infusion are 
represented for F (islet trans-
planted patients with function, m), 
NF (islet transplanted patients 
without function, s), CU (patients 
with chronic uveitis, r), and CON 
(normal subjects, h). j, repre-
sents the c-peptide concentration 
of pancreas transplanted patients 
during insulin infusion (17).
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measured every 10–30 min in the last hour of the basal period and ev-
ery 10 min throughout the study as previously described (Fig. 1 and
Table III) (10). Plasma glucose, free insulin, and c-peptide concentra-
tions were measured every minute in the initial 15 min of the hyper-
glycemic clamp to detect the first phase insulin release (14) and every
10–30 min thereafter (Fig. 2).
Free fatty acids (FFA) and lactate were measured in plasma every
20 min in the last hour of the basal state and throughout the studies
(Table IV).
 
Analytical determinations and calculations. 
 
Plasma glucose was
measured bedside with a Beckman glucose analyzer (10), free insulin
was measured by means of a RIA Incstar (Stillwater, Minnesota)
(10), c-peptide was measured by means of a RIA using a double-anti-
body (10), and glucagon, free fatty acids, lactate, tritiated glucose spe-
cific activity were measured as previously described (10). Deuterated
glucose enrichments were measured by means of gas-chromatogra-
phy/mass spectrometry with a technique using a derivatization of the
sample by means of boroacetylation (15). Hepatic glucose production
and peripheral glucose disposal were assessed as described previously
(10). The metabolic clearance rate of glucose (MCR) was calculated
by dividing the tissue glucose disposal by the corresponding plasma
glucose concentration in all study groups (1, 10).
Statistical analysis was performed using the CSS software (Com-
plete Statistical System; StatSoft Inc.). ANOVA with one between
groups factor and one repeated measures factor was used. Compari-
sons between groups were performed by the Scheffe test. When only
two groups were compared, the Student’s 
 
t
 
 test was used (16).
 
Results
 
Plasma glucose, insulin, c-peptide, and glucagon concentrations
in the basal state, during insulin infusion and during glucose in-
fusion in F, NF, CU, CON, and PAN. (Table III and Figs. 1
and 2).
 
In the post-absorptive state, the plasma glucose con-
centration was higher in NF (249
 
6
 
45 mg/dl) with respect to F
(114
 
6
 
9 mg/dl, 
 
P
 
 
 
,
 
 0.01), CU (87
 
6
 
4, 
 
P
 
 
 
,
 
 0.001) and CON
(88
 
6
 
2, 
 
P
 
 
 
,
 
 0.001). During the insulin clamp the glucose con-
centration was maintained constant at 98
 
6
 
3, 87
 
6
 
2, and 92
 
6
 
3
mg/dl in F, CU, and CON, respectively. In contrast, in NF, the
plasma glucose concentration was left to decrease to 
 
z
 
 180
mg/dl, level at which it was clamped for an additional 60–90
min. During the hyperglycemic clamp the plasma glucose con-
Figure 2. This figure depicts the 
experimental protocol of Study 2 
(175 mg/dl hyperglycemic clamp). 
The steady state post-absorptive 
concentrations as well as the time-
dependent variation of glucose, 
free insulin, and c-peptide during 
the 120 min glucose infusion are 
represented for F (m), CU (r), 
CON (h) , and PAN (j).
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centration was increased by 70–80 mg/dl above the post-
absorptive level by means of a 20% glucose infusion (185
 
6
 
7,
160
 
6
 
9, 162
 
6
 
9, and 162
 
6
 
7 mg/dl in F, CU, CON, and PAN, re-
spectively). Patients with nonfunctioning islet graft (NF) did
not receive the hyperglycemic stimulus.
The fasting plasma free insulin concentration was not sta-
tistically different in F, NF, and CU (10
 
6
 
2, 14
 
6
 
5, and 13
 
6
 
3
 
m
 
U/ml, respectively). The free insulin concentration was sig-
nificantly higher in F than in CON (10
 
6
 
2 vs. 6
 
6
 
1 
 
m
 
U/ml, 
 
P
 
 ,
0.05). During euglycemic hyperinsulinemia the insulin concen-
tration at plateau was not statistically different among the four
groups (7464, 7769, 7563, and 7263 mU/ml in F, NF, CU,
and CON, respectively). During the hyperglycemic clamp, the
peak of first phase insulin release was impaired in F (1–10 min,
1662 mU/ml), with respect to CU (3369; P , 0.05), CON
(2563; P , 0.05), and PAN (56615 mU/ml; P , 0.05). The sec-
ond phase insulin release (20–120 min of the hyperglycemic
clamp) was impaired in F (2165 mU/ml) with respect to CU
(58612; P , 0.05 with respect to F), CON (4568; P , 0.05),
and PAN (56610; P , 0.01).
The post-absorptive c-peptide concentration was higher in
PAN (3.760.1 ng/ml), with respect to F (1.960.6 ng/ml; P ,
0.05 with respect to PAN), CU (2.960.3 ng/ml; P , 0.05), and
CON (1.760.3; P , 0.01). Islet transplanted patients with no
function had a nearly absent basal c-peptide secretion (0.260.02
ng/ml). During euglycemic hyperinsulinemia, the inhibition of
c-peptide concentration was not significantly different be-
tween F and CON (42 and 50% of the basal, respectively;
Table III). F showed a lower decrement of c-peptide concen-
tration with respect to CU (P , 0.05), and the inhibition of
c-peptide concentration during insulin infusion was lacking in
PAN (Fig. 1). The data showing the lack of c-peptide inhibi-
tion during euglycemic hyperinsulinemia were partially previ-
ously reported (17). The increment of c-peptide above basal
during the hyperglycemic clamp was significantly defective in
F with respect to all groups. CU (4.260.8 ng/ml; P , 0.05 with
respect to F and CON) and PAN (5.960.9 ng/ml; P , 0.01 with
respect to F and CON) showed a higher early peak of insulin
secretion than F (2.860.5) and CON (2.160.5). The second
phase c-peptide release (20–120 minutes) did not differ be-
tween F (3.761.0 ng/ml) and CON (3.660.5 ng/ml; P 5 NS
with respect to F). The second phase c-peptide plateaus of F
(3.761.0 ng/ml) and CON (3.660.5) were significantly lower
than CU (9.261.8 ng/ml; P , 0.01) and PAN (7.561.1 ng/ml;
P , 0.01).
The post-absorptive glucagon concentration was higher in
F (141635 pg/ml; P , 0.05), NF (115627 pg/ml; P , 0.05), CU
(116621 pg/ml; P , 0.05), and PAN (135617 pg/ml; P , 0.01)
with respect to healthy subjects (CON, 7967 pg/ml). During
euglycemic hyperinsulinemia the plasma glucagon concentra-
tion was inhibited in F (141613 to 9569 pg/ml; P , 0.01 with
respect to basal) while showing a trend toward inhibition in
CU (116621 to 9769 pg/ml; P 5 NS) and CON (7967 to 7068
pg/ml; P 5 NS). In contrast, in NF (IDDM patients with non-
functioning islets) the glucagon concentration did not change
from the basal state during insulin infusion (115627 to 108622
pg/ml; P 5 NS). During hyperglycemia no significant variation
of glucagon concentration was observed in the groups F, CU,
CON, and PAN with respect to the basal condition.
Free fatty acids and lactate concentrations in the basal state,
during insulin infusion in F, NF, CU, CON, and PAN. Basal
free fatty acid concentration was similar in patients with islet
transplantation (F and NF, 7986150 and 5966233 mmol/liter,
respectively), in patients with chronic uveitis (CU, 757675
mmol/liter), and normal subjects (CON, 680695 mmol/liter).
During euglycemic hyperinsulinemia the inhibition of free fatty
acid concentration was not statistically different in IDDM pa-
tients with nonfunctioning islets (NF, 5966233 to 239629 mmol/
liter) with respect to F (7986150 to 8967 mmol/liter), CU
(757675 to 134632 mmol/liter), and CON (680695 to 115612
mmol/liter).
Post-absorptive blood lactate concentration was similar in
patients with functioning (F, 0.6060.20 mmol/liter) and non-
functioning islet transplant (NF, 0.9360.44 mmol/liter), in pa-
tients with chronic uveitis (CU, 0.9360.33 mmol/liter), and in
Table III. Glucose, Free Insulin, c-peptide, and Glucagon 
Plasma Concentrations in the Last Hour of the Basal State and 
in the Last Hour of the Euglycemic Insulin Clamp in IDDM 
Patients with Functioning Islet Graft (F), IDDM with Graft 
without Function (NF), Patients with Chronic Uveitis (CU), 
and Healthy Volunteers (CON)
F NF CU CON
Glucose
(mg/dl) Basal 11469§ 249645* 8764 8862
Insulin 9863§ 167635i 8762 9263
Free-IRI
(uU/ml) Basal 1062i 1465 1363i 661
Insulin 7464 7769 7563 7263
C-peptide
(ng/ml) Basal 1.960.6 0.260.02** 2.960.3 1.760.3
Insulin 1.160.3 0.360.1* 0.960.4 0.7960.09
Glucagon
(pg/ml) Basal 141635‡ 115627‡ 116621‡ 7967
Insulin 9569 108622 9769 7068
*Indicates P , 0.01 with respect to the basal; ‡indicates P , 0.05 with
respect to CON; §indicates P , 0.01 with respect to NF; iindicates P ,
0.01 with respect to CON; **indicates P , 0.001 with respect to CON.
Table IV. HGP, MCR, and Tissue Glucose Disposal (M) in 
the Last Hour of the Basal State (HGP and MCR), and during 
the Last Hour of the Euglycemic Insulin Clamp (HGP, MCR, 
and M) in IDDM Patients with a Functioning Graft (F), in 
IDDM Patients with a Graft without Function (NF), in 
Patients with CU and in Healthy Subjects (CON)
F NF CU CON
HGP (mg/kg/min)
Basal 2.460.2‡ 5.161.4§ 2.360.3‡ 2.260.2
Insulin 0.560.1* 1.360.2§ 0.260.1* 0.260.1*
MCR (ml/kg/min)
Basal 2.1260.16 1.6460.22i 2.5860.20 2.2160.16
Insulin 4.8160.80* 2.3360.36§¶ 4.7360.32* 8.0160.56*
M (mg/kg/min)
Insulin 5.360.6‡§ 3.960.5§ 4.160.4§ 7.460.3
*Indicates P , 0.01 with respect to the basal; ‡indicates P , 0.05 with
respect to NF; §indicates P , 0.01 with respect to CON; iindicates P ,
0.05 with respect to F and CU; ¶indicates P , 0.01 with respect to F and
CU.
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normal subjects (CON, 0.6860.36 mmol/liter). During eugly-
cemic hyperinsulinemia blood lactate concentration increased
in all groups with respect to the basal (F: from 0.6060.20 to
1.1760.23 mmol/liter, P , 0.05 with respect to the basal; NF:
from 0.9360.44 to 1.1960.32 mmol/liter, P 5 NS; CU: from
0.9360.33 to 1.0560.20 mmol/liter, P 5 NS; CON: from
0.6860.36 to 1.0360.25 mmol/liter; P , 0.05).
Hepatic glucose production and peripheral glucose disposal,
in the basal state and during insulin infusion (Table IV, Fig. 3).
Post-absorptive hepatic glucose output was higher in patients
with nonfunctioning islets (5.161.4 mg/kg/min) with respect to
patients with functioning graft (2.460.2; P , 0.05), patients
with chronic uveitis (2.360.3; P , 0.05), and healthy subjects
(2.260.2; P , 0.01). During the second hour of the euglycemic
hyperinsulinemic clamp (insulin concentration z 70 mU/ml)
the hepatic glucose production showed a similar decrement in
F (from 2.460.2 to 0.560.1 mg/kg/min), NF (from 5.161.4 to
1.360.2), CU (from 2.360.3 to 0.260.1), and CON (from
2.260.2 to 0.260.1). IDDM patients with no function (NF)
showed a persistently high hepatic glucose output both during
the first (1.661.0 mg/kg/min) and the second (1.360.2 mg/kg/
min) hour of hyperinsulinemia.
In the post-absorptive state, near steady state conditions of
glucose homeostasis do exist. Therefore, the total body glucose
uptake equals the hepatic glucose output. This value accounts
for the amount of glucose entering the utilizing tissues (tissue
glucose disposal) and for the urinary glucose losses (1). The
tissue glucose disposal calculated during the second hour of
the euglycemic insulin clamp was impaired in F (5.360.6 mg/
kg/min; P , 0.01), NF (3.960.5 mg/kg/min; P , 0.01), and CU
(4.160.4 mg/kg/min; P , 0.01) with respect to healthy subjects
(7.460.3 mg/kg/min). F had a peripheral glucose disposal sig-
nificantly higher than NF (P , 0.05).
Metabolic clearance rate (MCR) of glucose (Table IV).
The tissue glucose disposal is markedly influenced by the am-
bient glucose concentration. In fact, a high glucose level may
per se enhance the tissue glucose utilization independently of
the insulin concentration. Therefore, the M value for NF (in
the presence of hyperglycemia) is overestimated. A more ap-
propriate presentation of the data is achieved by factoring out
the glucose level, that is, by dividing the tissue glucose disposal
by the corresponding glucose concentration (glucose clear-
ance). In the basal state, the MCR of glucose of NF (1.6460.22
ml/kg/min) was significantly lower (P , 0.05) than F (2.1260.16),
CU (2.5860.20), and CON (2.2160.16). Similarly, during insu-
lin infusion, the increment of MCR above the basal value was
defective in NF (2.3360.36 ml/kg/min) with respect to F
(4.9160.80, P , 0.05), CU (4.3460.32, P , 0.05), and CON
(8.0160.56, P , 0.001).
Discussion
The intraportal injection of purified human islets under angio-
graphic guide is a fairly noninvasive procedure which entails
the injection of z 1 ml of islet tissue into the hepatic paren-
chyma. Metabolic studies in islet transplanted patients have
been limited by the scarce number of patients transplanted
successfully in any single center worldwide. Therefore, the op-
portunity to have eight patients with functioning islet grafts for
a minimum of 4 wk is rather unique. It is important to note
that intrahepatically injected islets can normalize glucose ho-
meostasis. In fact, islet clusters are engrafted in the periportal
spaces, completely surrounded by hepatocytes and Kupffer
cells (18). Therefore, the pathophysiology of insulin secretion
of a system constituted by pancreatic islets and liver is evi-
dently different from the physiological pancreatic insulin se-
cretion. Immediately after intrahepatic injection, the islets are
denervated and are vascularized by the portal vein blood. This
is surely a very unfavorable condition, since (a) the autonomic
modulation of insulin secretion is important in maintaining an
insulin secretory rate properly tuned to the glucohomeostatic
needs (17, 19, 20) and (b) the portal vein blood contains high
Figure 3. The figure represents the 
kinetics of inhibition of hepatic glu-
cose production in F (n), NF (s), 
CU (r), and CON (h) during insu-
lin infusion. NF show a markedly in-
creased basal hepatic glucose pro-
duction, which remains persistently 
high during insulin infusion. Basal 
and insulin-inhibited hepatic glu-
cose production appears to be nor-
mal in F.
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concentrations of metabolites of intestinal origin (i.e., glucose,
lactate, amino acids) as well as a high concentration of immu-
nosuppressive drugs (cyclosporin A, prednisone, azathioprine)
administered orally, which may have a toxic effect on the
b-cell function (19, 21, 22). Re-innervation by autonomic fi-
bers and neovascularization through the hepatic artery have
been shown to take place z 4–8 wk after transplant in the ro-
dent (23, 24).
Patients with functioning islets showed a near normal fast-
ing glycemia with a blood glucose level considerably lower
compared to patients without graft function. This indicates
that in the best clinical and metabolic conditions islet trans-
plant can normalize the plasma glucose concentration. This
finding agrees with results obtained by transplanting the pan-
creas (5–13, 17). In z 10–20% of cases, IDD patients with an
intact pancreas graft experience episodic hypoglycemic symp-
toms (11, 12), and the reason for this is still under debate. To
our knowledge no hypoglycemic episode was described in islet
transplanted patients. The fasting plasma insulin concentration
in patients after islet transplantation was approximately dou-
ble that of healthy subjects (10 vs. 6 mU/ml). The difference
may be partially explained by the chronic prednisone therapy
(shown to enhance insulin secretion [25]), since the group of
patients with chronic uveitis (on the same dose of prednisone)
also had a higher insulin level. Interestingly, the glucose/insu-
lin ratio is not statistically different between F and CON in the
basal state. This finding probably indicates that a new gluco-
homeostatic steady state has been achieved in F patients.
We showed that the basal hepatic glucose production is
nearly normal in patients with functioning islet transplantation
(Table IV). In contrast, the basal hepatic glucose output was
significantly increased in islet transplanted patients without
function. Interestingly, when the basal hepatic glucose output
was correlated with the prednisone dose, a positive correlation
was found (r 5 0.68; P , 0.01), while no correlation was found
between basal hepatic glucose production and cyclosporin A
(r 5 20.25; P 5 NS). These relationships indicate that pred-
nisone is more detrimental to glucose homeostasis than cy-
closporin A. Quite surprisingly, no correlation was found be-
tween the fasting hepatic glucose production and the fasting
c-peptide (r 5 20.25; P 5 NS) as well as between hepatic glu-
cose production and the number of islets transplanted (r 5
20.26; P 5 NS). This indicates that factors other than the
secretory capacity of the graft and the total number of islets
transplanted may play a crucial role in determining the success
of an islet implant. Although some patients with function were
still injecting a few units of insulin daily, we are convinced that
the transplanted islets had the major impact on the metabolic
results. In fact, insulin therapy was withdrawn at least 36 h (in-
termediate-acting) and 18 h (regular) before commencement
of the study.
During euglycemic hyperinsulinemia, the absolute value of
hepatic glucose production was higher in NF with respect to all
groups (Fig. 3). This indicates the presence of a resistance to
the action of insulin at the liver site which may be caused by a
variety of factors such as chronic immunosuppressive therapy,
the site of transplantation, and an altered metabolic milieu. Is-
let transplanted patients with a functioning graft had a normal
inhibition of hepatic glucose production during euglycemic hy-
perinsulinemia, as previously shown by us in pancreas-trans-
planted patients (10). In normal physiology, insulin secretion is
regulated by the rise in glucose (and other substrates) concen-
tration over time and the secreted insulin reaches the liver via
the portal vein inhibiting the hepatic glucose output. There-
fore, we raised the glucose concentration for 2 h in F, mimick-
ing the glucose level after a meal (z 180 mg/dl). Interestingly,
all islet-transplanted patients had either a defective or an ab-
sent first phase insulin release when compared with patients
with chronic uveitis, healthy subjects, or pancreas-transplanted
patients (Fig. 2). In addition, also the second phase insulin (but
not c-peptide) release of islet transplanted patients was mark-
edly reduced with respect to patients with chronic uveitis and
healthy subjects. The discrepancy between the insulin and
c-peptide response in the 20–120 min period probably reflects
an insulin extraction by the liver different than that which oc-
curs in normals. The importance of the early phase of insulin
secretion in inhibiting the hepatic glucose production was pre-
viously demonstrated by us (14), as well as by other authors
(26). Therefore, the altered pattern of insulin secretion of islet-
transplanted patients may be responsible for the post-prandial
hyperglycemia which is still experienced by patients with a suc-
cessful islet graft. This metabolic alteration may eventually
cause a deterioration of the HbA1c level.
To demonstrate the overall improvement of glucose ho-
meostasis in patients with functioning graft, we showed a sig-
nificantly higher tissue glucose disposal (P , 0.05) and meta-
bolic clearance rate of glucose (P , 0.01) in this group with
respect to patients without function.
In conclusion, the major metabolic advantage of the endo-
crine pancreas transplantation over other therapeutic modali-
ties of treatment of IDDM is that it represents a closed-loop
system, with a secretory pattern elicited by glucose and other
secretagogue stimuli. Successful pancreas transplantation al-
ready has been shown to correct the metabolic abnormalities
of IDDM (5–13, 19, 27). In this work, we have demonstrated
that intraportal islet transplantation (a procedure associated
with a much lower morbidity) also normalizes hepatic glucose
production and improves tissue glucose utilization in a selected
cohort of diabetic patients.
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